What Is Milo Biotechnology?

Milo Biotechnology is company developing a therapy that increases muscle strength or decrease the rate of muscle atrophy for the treatment of muscular disorders.

The company’s technology, a gene therapy-based up-regulation of the muscle-strengthening follistatin protein, was developed at and is exclusively licensed from Nationwide Children’s Hospital (Ohio, U.S.A.).

In 2014 the therapy completed a Phase I/II clinical study in Becker Muscular Dystrophy establishing initial safety and efficacy.

Recent News


The Duchenne Alliance commits $500,000 to Dr. Jerry Mendell and Milo Biotechnology to fund first Duchenne Follistatin Gene Therapy Trial

Columbus and Cleveland, OH, November 10, 2014– The International Duchenne Alliance announced today that it will allocate $500,000 to Dr.... Read More →

Milo Biotechnology’s Follistatin Gene Therapy Increases Function in Becker Muscular Dystrophy Patients

Data published today in the journal Molecular Therapy demonstrates initial clinical proof of principle of a gene therapy to increase... Read More →
Back to Top